We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Arvinas Inc (ARVN) COM USD0.001

Sell:$46.97 Buy:$47.04 Change: $0.71 (1.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.71 (1.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.71 (1.49%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.

Contact details

5 Science Park
United States
+1 (203) 5351456

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.44 billion
Shares in issue:
68.00 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • John Houston
    Chairman of the Board, President, Chief Executive Officer
  • Sean Cassidy
    Chief Financial Officer
  • Ian Taylor
    Chief Scientific Officer
  • Jared Freedberg
    General Counsel
  • Ronald Peck
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.